title: Is Progression-Free Survival the Right End Point in Trials of Patients With Clearly Resectable, Borderline Resectable, and Unresectable Liver-Limited Colorectal Cancer?
authors.affiliation: University Campus Klinikum Oldenburg, Carl von Ossietzky University, North-West-German Cancer Center, Oldenburg, Germany Koehne.Claus-Henning@klinikum-oldenburg.de.
authors.forename: Claus-Henning
authors.initials: CH
authors.lastname: Köhne
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D008297:Male; D010818:Practice Patterns, Physicians'; D018631:ras Proteins / Q000235:genetics*
chemical_list: D018631:ras Proteins